Thursday, April 3, 2025

CP Scorecard

CP  Scorecard

Derived from Current Agreements, the partnering scorecard gives an instant overview of the top partnering deals in the life sciences by year.

The following article contains a snapshot of the largest deals by value for the year.

Our Current Agreements database stores and categorizes deal data dating as far back as 2000 saving you valuable time on your deal making research activities.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | 66 report titles focusing on different deal types from co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

Top partnering deals of 2025 valued at over US$500m.

Partners Date Value, US$m Subject Termsheet
Roche, Zealand Pharma Mar 2025 5250 Collaboration, development and licensing agreement for petrelintide as therapy for obesity

Key Deal Terms Summary

1. Agreement Overview

  • Parties:
read more
Novo Nordisk, Valo Health Jan 2025 4790 Research, development and licensing agreement for drug programmes in obesity, type 2 diabetes and cardiovascular disease

Parties Involved

  • Valo Health, Inc. – AI-driven drug discovery and development company
read more
AstraZeneca, Harbour Biomed Mar 2025 4575 Research, development and licensing agreement for next-generation therapeutic antibodies

Key Deal Terms Summary

Agreement Overview

  • Parties:
read more
AstraZeneca, Syneron Bio Mar 2025 3475 Licensing agreement for Synova platform

Key Deal Terms Summary

1. Agreement Overview

  • Parties:
read more
Sciwind Biosciences, Verdiva Bio Jan 2025 2470 Licensing and collaboration agreement for metabolic disease portfolio

Parties Involved

  • Sciwind Biosciences – A pre-commercial biopharmaceutical company
read more
Abbvie, Gubra Mar 2025 2225 Development and licensing agreement for an Amylin Analog for treatment of obesity

Key Deal Terms Summary

1. Agreement Overview

  • Parties:
read more
Abbvie, Xilio Therapeutics Feb 2025 2162 Collaboration and option agreement to develop novel tumor-activated immunotherapies

Key Deal Terms Summary

1. Agreement Overview

  • Companies
read more
Dren Bio, Sanofi Mar 2025 1900 Asset purchase agreement for bispecific myeloid cell engager for deep B-cell depletion

Key Deal Terms Summary

Agreement Overview

  • Structure:
read more
Gilead Sciences, LEO Pharma Jan 2025 1700 Development, licensing and option agreement for oral STAT6 program

Parties Involved

  • Gilead Sciences, Inc. (Nasdaq: GILD) – A global biopharmaceutical
read more
Abbvie, Neomorph Jan 2025 1640 Development and option agreement for molecular glue degraders for oncology and immunology

Parties Involved

  • AbbVie – A global biopharmaceutical company with expertise in
read more
Samsung Biologics Jan 2025 1400 Manufacturing agreement with pharmaceutical company based in European Union

Samsung Biologics Secures $1.4B European Manufacturing Contract

Contract Overview
-

read more
Boehringer Ingelheim, Synaffix Jan 2025 1300 Licensing agreement for ADC technology

Parties Involved

  • Boehringer Ingelheim – A global biopharmaceutical company focused on
read more
Eli Lilly, Magnet Biomedicine Feb 2025 1290 Collaboration and license agreement to discover and develop novel molecular glue medicines

Key Deal Terms Summary

1. Agreement Overview

  • Parties:
read more
ArriVent Biopharma, Lepu Biopharma Jan 2025 1207 Licensing agreement for MRG007

ArriVent BioPharma & Lepu Biopharma Exclusive License Agreement for MRG007

read more
Avenzo Therapeutics, DualityBio Jan 2025 1200 Licensing agreement for EGFR/HER3 antibody-drug conjugate

Parties Involved

  • Avenzo Therapeutics, Inc. – A clinical-stage biotechnology company
read more
CSPC Megalith Biopharmaceutical, Radiance Biopharma Feb 2025 1165 Licensing agreement for ROR-1 targeted antibody drug conjugate RB-164 (SYS6005)

Key Deal Terms Summary

1. Agreement Overview

  • Companies
read more
Innovent Biologics, Roche Jan 2025 1080 Licensing agreement for DLL3 antibody drug conjugate

Parties Involved

  • Innovent Biologics, Inc. – A leading biopharmaceutical company
read more
Orna Therapeutics, ReNAgade Therapeutics, Vertex Pharmaceuticals Jan 2025 1065 Research, development, licensing and option agreement for next generation approaches for sickle cell disease and transfusion-dependent beta thalassemia

Parties Involved

  • Orna Therapeutics (via ReNAgade Therapeutics Inc.) – Specializes in
read more
Abbvie, Simcere Pharmaceuticals Jan 2025 1055 Development and option agreement for trispecific antibody candidate in multiple myeloma

Parties Involved

  • Simcere Zaiming – Oncology-focused biopharmaceutical subsidiary of
read more
Oxford BioTherapeutics, Roche Mar 2025 1036 Research agreement to discover novel targets for antibody-based therapeutics for treatment of cancer

Key Deal Terms Summary

Agreement Overview

  • Parties:
read more
Light Horse Therapeutics, Novartis Jan 2025 1025 Licensing agreement for multi-target collaboration to identify and develop small molecule therapeutics

Parties Involved

  • Light Horse Therapeutics Inc. – A biotechnology company developing
read more
Dropshot Therapeutics, eTheRNA immunotherapies Jan 2025 950 Development and licensing agreement for RNA-based therapeutics for the multiple new drug candidates

Parties Involved

  • Boehringer Ingelheim – A global biopharmaceutical company focused on
read more
Ionis Pharmaceuticals, Ono Pharmaceutical Mar 2025 940 Licensing agreement for sapablursen for treatment of polycythemia vera

Key Deal Terms Summary

1. Agreement Overview

  • Parties:
read more
Kyorin Pharmaceutical, Novartis Mar 2025 832.5 Licensing and option agreement for KRP-M223

Key Deal Terms Summary

1. Agreement Overview

  • Parties:
read more
Biotronik, Teleflex Feb 2025 823 Asset purchase agreement for vascular intervention business

Key Deal Terms Summary

1. Agreement Overview

  • Teleflex
read more
BridGene Biosciences, Takeda Pharmaceutical Feb 2025 816 Collaboration and licensing agreement to discover small molecule drugs for immunology and neurology targets

**Key Deal Terms

1. Agreement Overview

  • BridGene Biosciences and
read more
Nippon Shinyaku, Regenxbio Jan 2025 810 Development and licensing agreement for RGX-121 and RGX-111 for MPS Diseases

Key Deal Terms Summary: REGENXBIO and Nippon Shinyaku Partnership for RGX-121 and RGX-111

read more
Eli Lilly, Mediar Therapeutics Jan 2025 786 Licensing agreement for WISP1 antibody MTX-463

Parties Involved

  • Mediar Therapeutics, Inc. – A clinical-stage biotechnology company
read more
Araris Biotech, Chugai Pharmaceutical Jan 2025 780 Research and option agreement for next-generation adcs using AraLinQ technology

Araris Biotech announced they entered Research Collaboration and Option to License Agreement under

read more
Black Diamond Therapeutics, Les Laboratoires Servier Mar 2025 780 Licensing agreement for BDTX-4933

Key Deal Terms Summary

Agreement Overview

  • Parties:
read more
AB2 Bio, Nippon Shinyaku Jan 2025 686 Option and licensing agreement for Tadekinig alfa for an ultra-rare autoimmune disease

Key Deal Terms Summary

1. Agreement Overview

  • AB2 Bio has entered into
read more
Pfizer, PostEra Jan 2025 610 Licensing agreement for antibody-drug-conjugate discovery

Parties Involved

  • PostEra – A biotechnology company specializing in AI-driven
read more
Insilico Medicine, Menarini, Stemline Therapeutics Jan 2025 550 Licensing agreement for AI discovered preclinical asset

Menarini and Stemline Therapeutics and Insilico Medicine announced companies have entered exclusive

read more
Biogen, Stoke Therapeutics Feb 2025 550 Collaboration and licensing agreement for zorevunersen for treatment of Dravet syndrome

Key Deal Terms Summary

1. Agreement Overview

  • Companies
read more
Merck and Co, WuXi Biologics Jan 2025 521 Asset purchase agreement for vaccines manufacturing facility

MSD has agreed to acquire the WuXi Vaccines manufacturing facility located in Dundalk, Co Louth

read more
Beijing InnoCare Pharma, Keymed Biosciences, Prolium Bioscience Jan 2025 520 Licensing and development agreement for CD20xCD3 bispecific antibody

Key Deal Terms of the InnoCare, KeyMed, and Prolium License Agreement for ICP-B02

read more
Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | 66 report titles focusing on different deal types from co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities